Not in the United States. No generic semaglutide has been approved by the FDA, and the compounded preparations most of this roster sells are a different regulatory category rather than a cheaper version of the same approved product. What a real generic would have to demonstrate has now been demonstrated once, in India, and the gap between that trial and a compounded vial is most of the pharmaceutical system [1].
Most of what this roster sells is not the branded drug, and that is most of why it costs what it costs. The question that follows is whether a copy does what the original does, and for almost everything on sale here the honest answer is that nobody has checked.
The trial that did check
Twenty-one centers in India enrolled 270 adults with a BMI of 30 or above, or 27 or above with hypertension, dyslipidemia or type 2 diabetes. They were randomized 2:1 to a synthetic semaglutide injection or to Wegovy, escalating from 0.25 mg to 2.4 mg weekly. The primary endpoint was percentage weight change at 24 weeks, and the trial was prospectively registered before it began.
Two hundred and forty-six of the 267 randomized patients completed. Weight fell 13.8% on the test product and 14.1% on the reference, a least-squares mean difference of 0.26 percentage points with a 95% CI of −0.86 to 1.39, inside the prespecified non-inferiority margin. The proportion reaching at least 5% weight loss was 96.40% against 98.80%, and at least 10% was 80.60% against 80.00%. Treatment-emergent adverse events occurred in 72.30% and 76.70%, mostly gastrointestinal. Immunogenicity was among the stated objectives; the abstract does not report its result, so this page does not either.
What is actually in the copies sold here
Laboratory work on follow-on and compounded GLP-1 products found impurity profiles that differed from the originator’s, and greater apparent immunogenicity in the assays used [2]. Every author on that paper works for the company that makes the original. That is a conflict to weigh rather than a reason to discard the analysis, and it is set out in tested by the company that makes the original.
A separate survey of US compounded semaglutide and tirzepatide products reached a plainer conclusion: the formulations are unique to each preparer, and their efficacy and safety are largely unknown [3]. A generic has to match a reference product. A compounded preparation is not required to match anything, which is why two vials bearing the same molecule name can differ in ways nobody has measured, including what else is in the vial.
Why the India trial is worth reading anyway
Because it establishes a standard rather than a comfort. Until now the argument about non-originator semaglutide has been conducted almost entirely in the abstract, with chemistry arguments, regulatory categories, and confident claims in both directions and no clinical comparison behind them.
This is a clinical comparison, and it shows what answering the question costs: a registered protocol, a named reference product, a prespecified margin, and two hundred and seventy people. Set against that bar, the regulatory categories permitting compounding are about who may prepare a drug and under what conditions, rather than about whether the result performs. the 503A and 503B distinction is frequently quoted as though it settled efficacy, and it does not address it.
What the trial does not cover
Twenty-four weeks is short for a weight-loss trial, where the landmark studies ran 68 or 72. One country, one manufacturer, one product. A non-inferiority result is a statement about a margin rather than a demonstration that two things are identical, and the interval here runs from −0.86 to 1.39.
None of that undermines it. The finding is what it says it is: at 24 weeks, on weight, in this population, the copy was not meaningfully worse.
What to take to a checkout
One question, and it is not about chemistry. Ask what evidence exists for the specific product being sold, rather than for semaglutide, and rather than for compounding as a category. For almost everything in the price check the honest answer is none, which is a different thing from evidence of a problem and should not be confused with one.
The floor beneath that is lower still. Sellers that ship with no prescription at all are a different market from the one this site tracks, and three of six such orders in one surveillance study never arrived.